Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial

Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression‐free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0–4 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell, Karlin, Lionel, Benboubker, Lotfi, Voog, Eric, Yoon, Sung‐Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Villarreal, Miguel, Twumasi‐Ankrah, Philip, Labotka, Richard, Rifkin, Robert M., Lonial, Sagar, Kumar, Shaji K., Rajkumar, S. Vincent, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660432/
https://www.ncbi.nlm.nih.gov/pubmed/38024593
http://dx.doi.org/10.1002/jha2.759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660432/
https://www.ncbi.nlm.nih.gov/pubmed/38024593
http://dx.doi.org/10.1002/jha2.759

Ejemplares similares